Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRO95780 · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PRO95780 | DRUG | Intravenous repeating dose |
| rituximab | DRUG | Intravenous repeating dose |
| bevacizumab | DRUG | Intravenous repeating dose |
| carboplatin | DRUG | Intravenous repeating dose |
| paclitaxel | DRUG | Intravenous repeating dose |
| placebo | DRUG | Intravenous repeating dose |
| FOLFOX | DRUG | Intravenous repeating dose |
| cetuximab | DRUG | Intravenous repeating dose |
| FOLFIRI regimen | DRUG | Intravenous repeating dose |
| irinotecan | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 18 years * Diagnosis of follicular, CD20-positive B-cell NHL * Progression of disease after an objective response or stable disease lasting \> 6 months following completion of the most recent rituximab-containing regimen * Measurable diseas...
PRO95780 is an investigational small molecule being studied in oncology. It has been evaluated in clinical trials for Non-Hodgkin's Lymphoma, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Colorectal Cancer. The drug is still in clinical development and is not approved for any indication.
PRO95780 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer indications.
PRO95780 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It has completed several trials, including Phase 1 and Phase 2 studies, but remains in early-stage development.
PRO95780 has been studied in four completed clinical trials. These include NCT00480831 in Non-Small Cell Lung Cancer, NCT00497497 in Colorectal Cancer, NCT00517049 in Non-Hodgkin's Lymphoma, and NCT00851136 in Metastatic Colorectal Cancer. All trials are completed.
PRO95780 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being developed by Roche and has been tested in combination with other therapies such as rituximab and bevacizumab.